Clinical Trials Directory

Trials / Completed

CompletedNCT01673269

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Texas Tech University Health Sciences Center, El Paso · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. The tube passes beyond the stomach and into an opening in the liver called the bile duct. Another small flexible endoscope is inserted inside the ERCP scope to directly visualize the bile duct to ensure that there are no cancers or stones in the bile duct and occasionally to take a sample from the bile duct. The purpose of our study is to examine wither performing this procedure can transmit bacteria from the bile duct to the main blood stream.

Detailed description

This is a prospective study to measure the frequency of bacteremia in patients undergoing ERCP with direct cholangioscopic examination of the Common Bile Duct "CBD". A blood culture will be drawn from patients prior to the procedure, 5 minutes after the procedure and 30 minutes after the procedure. The patient will be followed up for 7 days after procedure for fever and sepsis. The estimated sample size is 60 patients.

Conditions

Interventions

TypeNameDescription
OTHERBlood culture ( aerobic and anaerobic)Blood culture 5 minutes and 30 minutes after the procedure

Timeline

Start date
2012-07-01
Primary completion
2013-10-01
Completion
2013-10-01
First posted
2012-08-27
Last updated
2017-05-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01673269. Inclusion in this directory is not an endorsement.